Sharp and to the Point
The aim of this Challenge is to develop a device that enables injections in mice without losing material to dead space, allows needles to be changed quickly and safely between animals to ensure sharpness and sterility, and which prevents cross-contamination between animals. This must be competitively priced to facilitate broad uptake across the bioscience sector.
Active Needle Technology Ltd have been awarded £99,382 to deliver the project: Ultrasonic, low dead space needle with improved animal welfare. The team is led by Mr Ian Quirk.
Sponsored by AstraZeneca, GSK, The Royal Veterinary College and The University of Sheffield, this Challenge aims to develop a device that enables injections in mice without losing material to dead space, allows needles to be changed quickly and safely between animals to ensure sharpness and sterility, and which prevents cross-contamination between animals.
Hypodermic needles are used throughout medical research involving animals for injecting substances (e.g. via intravenous, subcutaneous, intraperitoneal or intramuscular routes) or for collecting blood samples. Most needles used to administer material parenterally in animals are designed and sold as single-use disposable needles.
Where needles are re-used, it is commonly done to reduce time and cost because of the involvement of large numbers of mice and/or test material. Two blogs published on the NC3Rs website have focused on the topic of re-using hypodermic needles in day-to-day practice and highlight the associated scientific and welfare concerns 1,2.
The re-use of needles results in a loss of sterility and can increase the risk of infection and disease transmission between individual animals and between cages. Re-use also risks dulling of the needle, potentially increasing the pain and discomfort associated with subsequent injections. These concerns create confounding and unnecessary variables which can impact the quality of scientific data collected.
When needles are re-used in mouse studies, it is most often to address the following:
- Loss of material to dead space. The primary reason for re-use of needles and syringes is loss of valuable material (such as cells, compounds, viruses) in the fluid not expelled due to dead space between the syringe and the needle hub. The materials used in pilot studies are often difficult and expensive to synthesise and are therefore made in small quantities. This, combined with the size of mice and the small volumes administered, mean dead space losses can form a significant percentage of the material needed. An increasing number of studies involve the injection of living cells for example, for xenograft models used in oncology research. To account for dead space losses during administration, an excess of cells is needed. For certain cell lines, these can be difficult to grow and harvest in large quantities without affecting their quality.
- The time needed to change needles between injections. This can be a concern for studies where materials may need to be injected within a limited time into large numbers of animals. For example, changing the needle for each animal in a study where the formulation stability requires all animals to be dosed within an hour of formulation preparation would require additional staff to complete the injections within the necessary timeframe.
It is possible to purchase low dead space needles and syringes. However, they are not available in all needle gauges, and the syringe barrels are often difficult to read for small volumes which can affect the accuracy of small volumes draws. Insulin syringes have been developed that have no dead space. However, these are supplied with the needle attached making them inappropriate for use with substances that cannot be drawn up through the needle (e.g. cells).
All currently available products require significant time to manually change a needle between each animal.
There is evidence to show that the single use of a needle can cause significant dulling/deformity of the needle tip 1, and that re-use of these needles may cause transient pain 3,4 and tissue damage at the site of injection. The transfer of material between animals (blood/tissue) can also increase the risk of infection and cross-contamination between cages of mice may occur. Infection and disease transmission can lead to study failure and result in further animal use and welfare concerns as well as loss of time and money. Use of needles more than once can also affect the quality of the scientific data collected as each animal in the cage is treated differently with respect to the process of injection.
In 2017, 1.89 million animals were used in experimental procedures in the UK. Approximately 58% were mice and many of these would have been involved in procedures involving an injection for example, for basic research programmes, administration of materials in efficacy, toxicity and pharmacokinetic studies, or in vaccine batch testing for quality and safety. A small refinement in how substances are delivered would positively impact a high number of animals.
Full Challenge information
Project team led by:
- Mr Ian Quirk, Active Needle Technology Ltd, £99,382
Challenge Panel membership
|Dr Martino Picardo (Chair)||Independent|
|Dr Sally Robinson (Sponsor)||AstraZeneca|
|Dr Sam Izzard (Sponsor)||GSK|
|Dr Sue Sparrow (Sponsor)||GSK|
|Dr Helen Marriott (Sponsor)||The University of Sheffield|
|Dr Lucy Whitfield (Sponsor)||Royal Veterinary College London|
|Mrs Margaret Parton||Independent|
|Mr James Bussell||University of Oxford|
|Professor Paul Flecknell||Newcastle University|
|Mr Ian Rosewell||The Francis Crick Institute|
|Professor Dionysios Douroumis||University of Greenwich|